REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by ...

(RTTNews) - INmune Bio, Inc. (INMB), on Tuesday presented baseline demographics and disease characteristics of participants in its MINDFuL Phase II clinical trial at the AD/PD 2025 Conference in ...

New feature delivers the industry’s most comprehensive, consent-based financial and tax summary – enabling smarter decisions, streamlined planning, and better client outcomes Designed to revolutionize ...

Patients with hereditary angioedema had lower attack rates, improved health-related quality of life and improved disease control with lanadelumab regardless of attack frequency at baseline, according ...